Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

• Status: Completed
• Trial end date: 1969-12-31

Summary

To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days) in healthy male subjects between Japanese and Caucasians

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Dabigatran